

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently Amended) A process for manufacture of long circulating non-pegylated liposomes comprising:
 dissolving one or more phospholipids and one or more sterols in a solvent or mixture of solvents;
 wherein the one or more phospholipids is a saturated phosphatidylcholine selected from the group consisting of distearoyl phosphatidylcholine (DSPC), hydrogenated soya phosphatidylcholine (HSPC) and mixtures thereof;
 removing the solvent or mixture of solvents and adding an aqueous hydration media to the phospholipids and sterols; or adding an aqueous hydration media to the phospholipids and sterols in the solution; and removing the solvent or mixture of solvents;
 wherein the aqueous hydration media comprises consists essentially of ammonium sulfate and sucrose and the amount of aqueous hydration media used is in the range of 10 to 35 ml for each mmole of phospholipid present to form long circulating non-pegylated liposomes;
 and
 removing ammonium sulphate from extra liposomal hydration medium by dialysis using a sucrose-histidine buffer solution.
2. (Previously presented) The process of claim 1 wherein the amount of aqueous hydration media used is 30 ml for each mmole of phospholipid in the lipid solution.
3. (Previously presented) The process of manufacture of non-pegylated liposomes of claim 1 further comprising loading the liposomes with a therapeutic or diagnostic agent after removal of the ammonium sulphate from the extra liposomal hydration medium.
4. (Previously presented) The process of claim 3, wherein the therapeutic agent is an antineoplastic agent.

5. (Previously presented) The process of claim 4, wherein the antineoplastic agent is selected from the group consisting of Doxorubicin hydrochloride, Daunorubicin hydrochloride, and Epirubicin hydrochloride.
6. (Previously presented) The process of claim 5, wherein the antineoplastic agent is Doxorubicin hydrochloride.
7. (Previously presented) The process of claim 1, wherein the molar ratio of phospholipid to sterol is from about 1:0.1-1:2.
8. (Previously presented) The process of claim 7, wherein the molar ratio of phospholipid to sterol is about 1:0.7.
9. (Canceled)
10. (Previously presented) The process of claim 1, wherein the concentration of ammonium sulfate in aqueous hydration media is not less than 125 mmoles/liter.
11. (Canceled)
12. (Previously presented) The process of claim 1, wherein the phospholipid has a minimum of sixteen carbons fatty acid chain.
13. (Canceled)
14. (Previously presented) The process of claim 1, wherein the phospholipid is distearoyl phosphatidylcholine (DSPC) and wherein the sterol is cholesterol.
15. (Previously presented) The process of claim 1, wherein the non-pegylated liposomes are successively extruded through series of filters having pore sizes from 0.4 μm to 0.05 μm for sizing.

16. (Previously presented) A liposome manufactured by the process of claim 1.
17. (Previously presented) The liposome of claim 16, wherein the phospholipid comprises distearoyl phosphatidylcholine (DSPC) and the sterol comprises cholesterol.
18. (Previously presented) The liposome of claim 16, wherein the non-pegylated liposome further comprises a therapeutic or diagnostic agent.
19. (Previously presented) The liposome of claim 18, wherein said therapeutic agent comprises an antineoplastic agent.
20. (Previously presented) The liposome of claim 19, wherein the antineoplastic agent is selected from the group consisting of Doxorubicin hydrochloride, Daunorubicin hydrochloride, and Epirubicin hydrochloride.
21. (Previously presented) The liposome of claim 20, wherein the antineoplastic agent is Doxorubicin hydrochloride.
22. (Previously presented) The liposome of claim 16, wherein the average size of liposome is 0.06 μm to 0.16 μm in diameter.
- 23-62. (Canceled)
63. (Currently Amended) A process for manufacture of non-pegylated liposomes comprising: forming a lipid film by evaporating a solvent from a lipid solution comprising one or more phospholipids, a sterol, and a solvent; and hydrating the lipid film by adding an aqueous hydration media to form a non-pegylated liposomal composition; wherein the aqueous hydration media comprises consists essentially of ammonium sulfate and sucrose and wherein the amount of aqueous hydration media used is in the range of 10 to 35 ml for each mmole of phospholipid present in the lipid solution; and

removing ammonium sulphate from extra liposomal hydration medium using a sucrose-histidine buffer solution.

64. (Previously presented) The process of Claim 63 wherein the aqueous hydration media comprises greater than 125 mM ammonium sulfate and 100 mM to 500mM sucrose.
65. (Previously presented) The process of Claim 63 wherein the aqueous hydration media comprises greater than 125 mM ammonium sulfate and 250 mM to 300 mM sucrose.
66. (Previously presented) The process of Claim 63 wherein the amount of histidine in the sucrose-histidine buffer is 1 mM to 100 mM.
67. (Previously presented) The process of Claim 63 wherein amount of histidine in the sucrose-histidine buffer is 8 to 12 mM.
68. (Previously presented) The process of Claim 63 wherein amount of histidine in the sucrose-histidine buffer is 10 mM.
69. (Previously presented) The process of Claim 1 wherein the long circulating non-pegylated liposomes have a blood circulation half life of at least 25 times longer than conventional non-liposomal formulations when tested in Swiss albino mice at equivalent doses.